GLOBE LIFE INC. quarterly report, Q2 FY2014

Business context and reporting period

Entity discrepancy: The request names Globe Life Inc., but this filing identifies the registrant as Torchmark Corporation. This summary reflects the Torchmark 10-Q for the quarter and six months ended June 30, 2014; confirm the filing is for the intended issuer. Torchmark primarily sells life and supplemental health insurance and manages the investments supporting policy obligations.

Financial performance

• Six-month premium revenue was $1.619 billion, up 4.4%; net investment income was $363.9 million, up 2.6%.
• Six-month policyholder benefits rose to $1.142 billion from $1.077 billion. Pretax income was $377.2 million, up 3.1%.
• Life underwriting margin was $281.3 million, up 5%, with a 29% margin rate versus 28%. Health margin declined 1% to $99.2 million, at 23% of premium. Medicare Part D margin rose 12% to $18.2 million, or 11% of premium.
• At June 30, total assets were $19.652 billion and shareholders’ equity was $4.509 billion. Cash and short-term investments totaled approximately $94 million.
• Debt comprised $275 million of commercial paper and $991 million of long-term debt. Debt to capitalization was 21.9% under GAAP; reported interest coverage was 10.9 times.

Material changes versus comparable periods

• Q2 net income declined despite higher revenue, while first-half net income and diluted EPS increased. For the six months, realized investment gains contributed $11.2 million after tax, versus $0.1 million in 2013.
• Life premiums increased 4%; non-Part-D health premiums declined 1%. Medicare Part D premiums rose 12%, and Part D net sales increased to $51.6 million from $16.9 million, mainly due to automatic enrollees and employer-group activity.
• Management separated Medicare Part D as a standalone reporting segment effective January 1, 2014; prior segment results were adjusted for comparison.
• Net unrealized gains on fixed maturities rose to approximately $1.4 billion from $390 million at year-end 2013, largely reflecting lower market interest rates. This lifted reported equity, but does not represent realized earnings.
• Share repurchases totaled $238.3 million in the first half. The company completed a three-for-two stock split on July 1, 2014; reported historical per-share data reflects the split.

Outlook, risks and unusual items

• Management expected full-year 2014 Medicare Part D margin of approximately 8%–11% of premium, a decline of about 2–3 percentage points, primarily because costly Hepatitis C drugs were not included in the filed pricing. It expected interim GAAP-versus-segment Part D differences to eliminate by year-end.
• Management cited a moderating impact from low interest rates on portfolio yields; the six-month fixed-maturity portfolio yield was 5.92% versus 5.97%. It noted callable higher-yielding bonds could reduce future investment income if called and reinvested at lower rates.
• First-half unusual items included $3.1 million of administrative settlements for previously unfiled death claims, $3.7 million net litigation accruals, and $1.3 million received from investment-litigation settlements. The company expected additional administrative settlements but could not estimate their extent.
• A confidential settlement was reached in May 2014 in the California agent classification case. Unclaimed-property audits involving 47 states remained ongoing; the company could not estimate potential loss contingencies. Management did not expect litigation overall to materially affect financial condition, results, or liquidity, while acknowledging punitive-damage uncertainty.
• The company reported no material change in risk factors or market-risk exposure and stated disclosure controls were effective. Forward-looking risks include insurance claims and lapses, regulation and Medicare changes, interest rates, investment credit quality, competition, litigation, and premium-rate approvals.

Important facts for investors to verify

• Confirm Torchmark Corporation is the intended issuer, rather than Globe Life Inc.
• Review the drivers of Q2 net-income decline and the contribution of realized gains to first-half earnings.
• Assess Part D margin assumptions and exposure to Hepatitis C drug costs, enrollment mix, and CMS rule changes.
• Examine portfolio credit quality and interest-rate sensitivity: 96% of fixed maturities were investment grade, while $563 million were below investment grade.
• Verify liquidity and capital capacity, including the new $750 million credit facility, commercial-paper usage, insurance-subsidiary dividend expectations, and regulatory capital position.
• Monitor outcomes of unclaimed-property audits and any further death-claim settlements; the filing provides no clear estimate of potential audit-related losses.